MicroStrategy
MSTR
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Meritage Homes
MTH
US Stock MarketDetailed Quotes
ONCY Oncolytics Biotech
- 0.831
- -0.056-6.36%
Close Dec 20 16:00 ET
- 0.831
- 0.0000.00%
Post 16:20 ET
64.05MMarket Cap-3.32P/E (TTM)
0.900High0.790Low546.37KVolume0.870Open0.887Pre Close461.60KTurnover0.72%Turnover RatioLossP/E (Static)77.07MShares1.53052wk High10.13P/B62.96MFloat Cap0.71052wk Low--Dividend TTM75.76MShs Float7.400Historical High--Div YieldTTM12.40%Amplitude0.351Historical Low0.844Avg Price1Lot Size
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Oncolytics Biotech Stock Forum
Oncolytics Biotech Reveals Presentation Of Two Data Sets Through Two Abstracts Showcasing Pelareorep's Potential In Difficult-to-treat Gastrointestinal Cancers At ASCO
Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort
Tuesday, 3rd December at 7:00 am
Early safety and tolerability results from six randomized patients support continued enrollment of pelareorep combined with modified FOLFIRINOX, with or without atezolizumab
The study will begin with 30 patients, with an option to expand to an additional 34 participants
SAN DIEGO and CALGARY, AB, Dec. 3, 20...
Earnings report and updates tomorrow morning before opening. It's overdue. We're they waiting for something to announce?? GLTA.
Watch for results coming out of mFOLFIRINOX PELAREOREP and Roche’s Tecentriq. We should get safety results on a few patients by EOY. If we get good tumor shrinkage like in last trial with GEM and PAX, we should be off and running with two potential treatments for Pancreatic Cancer. 2025 might be our buyout year. GLTA.
MT Newswires· 2 mins ago
07:05 AM EDT, 10/04/2024 (MT Newswires) -- Oncolytics Biotech Brief: Announcing "Key Progress" and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Preparing for FDA Accelerated Approval Path
Pancreatic cancer data will be good, just have to wait a bit more. Good results from mFOLFIRINOX safety trial hopefully before EOY. GLTA. All new analysts targets are higher and rated overweight.
No comment yet